瓣中瓣TAVR与再次外科主动脉瓣置换的住院结局与再入院比较
基于美国2012-16年全国再入院数据库,比较退化生物瓣患者接受瓣中瓣经导管主动脉瓣置换(VIV-TAVR,n=3443)与孤立再次外科主动脉瓣置换(re-SAVR,n=3372)的30天结局。多因素分析和倾向评分匹配(2181对)显示,VIV-TAVR与更低的30天死亡率、发病率和重大出血风险相关,且住院时间更短、常规回家出院率更高。
要点
- VIV-TAVR较re-SAVR的30天死亡率更低(匹配后OR 0.41,95%CI 0.23-0.74)。
- VIV-TAVR重大出血风险更低(匹配后OR 0.66,95%CI 0.51-0.85)。
- VIV-TAVR住院时间中位缩短2天,常规回家出院几率更高(OR 2.11)。
核心结论
- 在高危退化生物瓣患者中,VIV-TAVR在30天死亡率、发病率和出血并发症方面优于re-SAVR。
研究设计与样本
- 利用美国2012-16年全国再入院数据库的回顾性队列研究,纳入VIV-TAVR患者3443例和孤立re-SAVR患者3372例。
- 采用多因素分析和倾向评分匹配(1:1,2181对)比较30天结局。
主要发现
- 未调整分析中,VIV-TAVR的30天死亡率2.7% vs. re-SAVR 5.0%,30天发病率66.4% vs. 79%,重大出血率35.8% vs. 50%。
- 多因素分析中,re-SAVR是30天死亡率的显著危险因素(VIV-TAVR vs. re-SAVR的aOR 0.48,95%CI 0.28-0.81)。
- 匹配后,VIV-TAVR与更低的30天死亡率(OR 0.41,95%CI 0.23-0.74)、30天发病率(OR 0.53,95%CI 0.43-0.72)和重大出血(OR 0.66,95%CI 0.51-0.85)相关。
- VIV-TAVR与更短住院时间(中位节省2天,95%CI 1.3-2.7)和更高常规回家出院几率(OR 2.11,95%CI 1.61-2.78)相关。
临床怎么用
- 对于高外科风险的退化生物瓣患者,VIV-TAVR可作为re-SAVR的替代选择,可能降低30天死亡、发病和出血风险。
局限性
- 研究为回顾性数据库分析,结论需在低危和中危患者中进一步验证,并需充分评估长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We sought to perform a head-to-head comparison of contemporary 30-day outcomes and readmissions between valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) patients and a matched cohort of high-risk reoperative surgical aortic valve replacement (re-SAVR) patients using a large, multicentre, national database. METHODS AND RESULTS: We utilized the nationally weighted 2012-16 National Readmission Database claims to identify all US adult patients with degenerated bioprosthetic aortic valves who underwent either VIV-TAVR (n = 3443) or isolated re-SAVR (n = 3372). Thirty-day outcomes were compared using multivariate analysis and propensity score matching (1:1). Unadjusted, VIV-TAVR patients had significantly lower 30-day mortality (2.7% vs. 5.0%), 30-day morbidity (66.4% vs. 79%), and rates of major bleeding (35.8% vs. 50%). On multivariable analysis, re-SAVR was a significant risk factor for both 30-day mortality [adjusted odds ratio (aOR) of VIV-SAVR (vs. re-SAVR) 0.48, 95% confidence interval (CI) 0.28-0.81] and 30-day morbidity [aOR for VIV-TAVR (vs. re-SAVR) 0.54, 95% CI 0.43-0.68]. After matching (n = 2181 matched pairs), VIV-TAVR was associated with lower odds of 30-day mortality (OR 0.41, 95% CI 0.23-0.74), 30-day morbidity (OR 0.53, 95% CI 0.43-0.72), and major bleeding (OR 0.66, 95% CI 0.51-0.85). Valve-in-valve TAVR was also associated with shorter length of stay (median savings of 2 days, 95% CI 1.3-2.7) and higher odds of routine home discharges (OR 2.11, 95% CI 1.61-2.78) compared to re-SAVR. CONCLUSION: In this large, nationwide study of matched high-risk patients with degenerated bioprosthetic aortic valves, VIV-TAVR appears to confer an advantage over re-SAVR in terms of 30-day mortality, morbidity, and bleeding complications. Further studies are warranted to benchmark in low- and intermediate-risk patients and to adequately assess longer-term efficacy.
引用
- Hirji SA, Percy ED, Zogg CK, et al. Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes. Eur Heart J. 2020. PMID: 32445575. doi:10.1093/eurheartj/ehaa252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。